vs
Side-by-side financial comparison of Enovis CORP (ENOV) and INTEGRA LIFESCIENCES HOLDINGS CORP (IART), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
Enovis CORP is the larger business by last-quarter revenue ($548.9M vs $434.9M, roughly 1.3× INTEGRA LIFESCIENCES HOLDINGS CORP). On growth, INTEGRA LIFESCIENCES HOLDINGS CORP posted the faster year-over-year revenue change (-1.7% vs -2.2%). Enovis CORP produced more free cash flow last quarter ($29.1M vs $-5.4M). Over the past eight quarters, Enovis CORP's revenue compounded faster (9.8% CAGR vs 8.6%).
Enovis Corporation is a medical technology company with a focus in orthopedics. The company was founded by brothers Mitchell and Steven Rales as the Colfax Corporation in 1995. Enovis is headquartered in Wilmington, Delaware and is listed on the NYSE as ENOV. The company has over 5,000 employees operating at 12 sites around the world.
Integra LifeSciences Holdings Corporation is a global medical device manufacturing company headquartered in Princeton, New Jersey. Founded in 1989, the company manufactures products for skin regeneration, neurosurgery, reconstructive and general surgery. Integra artificial skin became the first commercially reproducible skin tissue used to treat severe burns and other skin wounds.
ENOV vs IART — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $548.9M | $434.9M |
| Net Profit | $-571.1M | — |
| Gross Margin | 59.9% | 50.8% |
| Operating Margin | -101.7% | 5.3% |
| Net Margin | -104.1% | — |
| Revenue YoY | -2.2% | -1.7% |
| Net Profit YoY | 18.8% | — |
| EPS (diluted) | $-9.99 | $-0.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $548.9M | $434.9M | ||
| Q3 25 | $564.5M | $402.1M | ||
| Q2 25 | $558.8M | $415.6M | ||
| Q1 25 | — | $382.7M | ||
| Q4 24 | $561.0M | $442.6M | ||
| Q3 24 | $505.2M | $380.8M | ||
| Q2 24 | $525.2M | $418.2M | ||
| Q1 24 | $516.3M | $368.9M |
| Q4 25 | $-571.1M | — | ||
| Q3 25 | $-36.7M | $-5.4M | ||
| Q2 25 | $-56.0M | $-484.1M | ||
| Q1 25 | — | $-25.3M | ||
| Q4 24 | $-703.2M | — | ||
| Q3 24 | $-31.5M | $-10.7M | ||
| Q2 24 | $-18.6M | $-12.4M | ||
| Q1 24 | $-72.0M | $-3.3M |
| Q4 25 | 59.9% | 50.8% | ||
| Q3 25 | 59.3% | 51.5% | ||
| Q2 25 | 59.5% | 50.4% | ||
| Q1 25 | — | 50.8% | ||
| Q4 24 | 54.8% | 56.3% | ||
| Q3 24 | 56.7% | 52.6% | ||
| Q2 24 | 55.0% | 54.0% | ||
| Q1 24 | 57.7% | 56.1% |
| Q4 25 | -101.7% | 5.3% | ||
| Q3 25 | -3.0% | 2.9% | ||
| Q2 25 | -8.4% | -123.4% | ||
| Q1 25 | — | -4.0% | ||
| Q4 24 | -118.5% | 8.0% | ||
| Q3 24 | -6.3% | -2.1% | ||
| Q2 24 | -8.4% | -0.7% | ||
| Q1 24 | -6.8% | 1.1% |
| Q4 25 | -104.1% | — | ||
| Q3 25 | -6.5% | -1.3% | ||
| Q2 25 | -10.0% | -116.5% | ||
| Q1 25 | — | -6.6% | ||
| Q4 24 | -125.4% | — | ||
| Q3 24 | -6.2% | -2.8% | ||
| Q2 24 | -3.5% | -3.0% | ||
| Q1 24 | -13.9% | -0.9% |
| Q4 25 | $-9.99 | $-0.03 | ||
| Q3 25 | $-0.64 | $-0.07 | ||
| Q2 25 | $-0.98 | $-6.31 | ||
| Q1 25 | — | $-0.33 | ||
| Q4 24 | $-12.69 | $0.25 | ||
| Q3 24 | $-0.58 | $-0.14 | ||
| Q2 24 | $-0.34 | $-0.16 | ||
| Q1 24 | $-1.32 | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $33.6M | $263.7M |
| Total DebtLower is stronger | $1.4B | $726.6M |
| Stockholders' EquityBook value | $2.0B | $1.0B |
| Total Assets | $4.4B | $3.6B |
| Debt / EquityLower = less leverage | 0.67× | 0.70× |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $33.6M | $263.7M | ||
| Q3 25 | $44.1M | $267.9M | ||
| Q2 25 | $38.5M | $253.6M | ||
| Q1 25 | — | $273.3M | ||
| Q4 24 | $48.2M | $273.6M | ||
| Q3 24 | $35.4M | $277.6M | ||
| Q2 24 | $35.0M | $296.9M | ||
| Q1 24 | $66.3M | $663.1M |
| Q4 25 | $1.4B | $726.6M | ||
| Q3 25 | $1.4B | $736.3M | ||
| Q2 25 | $1.4B | $745.9M | ||
| Q1 25 | — | $755.6M | ||
| Q4 24 | $1.3B | $760.5M | ||
| Q3 24 | $1.3B | $765.3M | ||
| Q2 24 | $1.3B | $770.2M | ||
| Q1 24 | $1.3B | $775.0M |
| Q4 25 | $2.0B | $1.0B | ||
| Q3 25 | $2.6B | $1.0B | ||
| Q2 25 | $2.6B | $1.0B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | $2.6B | $1.5B | ||
| Q3 24 | $3.3B | $1.5B | ||
| Q2 24 | $3.3B | $1.5B | ||
| Q1 24 | $3.3B | $1.6B |
| Q4 25 | $4.4B | $3.6B | ||
| Q3 25 | $5.0B | $3.6B | ||
| Q2 25 | $4.9B | $3.7B | ||
| Q1 25 | — | $4.1B | ||
| Q4 24 | $4.7B | $4.0B | ||
| Q3 24 | $5.6B | $4.1B | ||
| Q2 24 | $5.4B | $4.1B | ||
| Q1 24 | $5.5B | $4.1B |
| Q4 25 | 0.67× | 0.70× | ||
| Q3 25 | 0.54× | 0.71× | ||
| Q2 25 | 0.53× | 0.72× | ||
| Q1 25 | — | 0.50× | ||
| Q4 24 | 0.52× | 0.49× | ||
| Q3 24 | 0.40× | 0.50× | ||
| Q2 24 | 0.41× | 0.50× | ||
| Q1 24 | 0.40× | 0.48× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $82.6M | $11.8M |
| Free Cash FlowOCF − Capex | $29.1M | $-5.4M |
| FCF MarginFCF / Revenue | 5.3% | -1.2% |
| Capex IntensityCapex / Revenue; lower = less reinvestment burden | 9.7% | 4.0% |
| Cash ConversionOCF / Net Profit; >1× = earnings back up with cash | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $22.8M | $-31.1M |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $82.6M | $11.8M | ||
| Q3 25 | $47.8M | $40.9M | ||
| Q2 25 | $-1.6M | $8.9M | ||
| Q1 25 | — | $-11.3M | ||
| Q4 24 | $88.3M | $50.7M | ||
| Q3 24 | $53.6M | $22.5M | ||
| Q2 24 | $7.8M | $40.4M | ||
| Q1 24 | $-36.2M | $15.8M |
| Q4 25 | $29.1M | $-5.4M | ||
| Q3 25 | $3.4M | $25.8M | ||
| Q2 25 | $-44.9M | $-11.2M | ||
| Q1 25 | — | $-40.2M | ||
| Q4 24 | $35.1M | $21.1M | ||
| Q3 24 | $2.4M | $-7.2M | ||
| Q2 24 | $-31.6M | $10.7M | ||
| Q1 24 | $-73.1M | $291.0K |
| Q4 25 | 5.3% | -1.2% | ||
| Q3 25 | 0.6% | 6.4% | ||
| Q2 25 | -8.0% | -2.7% | ||
| Q1 25 | — | -10.5% | ||
| Q4 24 | 6.3% | 4.8% | ||
| Q3 24 | 0.5% | -1.9% | ||
| Q2 24 | -6.0% | 2.6% | ||
| Q1 24 | -14.2% | 0.1% |
| Q4 25 | 9.7% | 4.0% | ||
| Q3 25 | 7.9% | 3.8% | ||
| Q2 25 | 7.7% | 4.8% | ||
| Q1 25 | — | 7.6% | ||
| Q4 24 | 9.5% | 6.7% | ||
| Q3 24 | 10.1% | 7.8% | ||
| Q2 24 | 7.5% | 7.1% | ||
| Q1 24 | 7.2% | 4.2% |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
Revenue Breakdown by Segment
ENOV
| Reconstructive Segment | $258.0M | 47% |
| Surgical | $129.0M | 23% |
| Prevention And Recovery | $92.6M | 17% |
| Other Prevention And Recovery | $71.4M | 13% |
IART
| Neurosurgery | $226.2M | 52% |
| Asia Pacific | $53.7M | 12% |
| Instruments | $52.3M | 12% |
| ENT | $44.8M | 10% |
| Other | $38.9M | 9% |
| Rest Of The World | $19.0M | 4% |
